玛仕度肽注射液 | China Drugs ListMazdutide Injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 信达生物制药（苏州）有限公司Innovent Biologics (Suzhou) Co., Ltd.
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 内分泌与代谢Endocrinology & metabolism
- 公开来源记录的适应症
- 1. 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制, 初始体重指数(BMI)为: ● BMI≥28 kg/m2(肥胖),或 ● BMI≥24 kg/m 2(超重) ,并伴有至少一种体重相关的合并症(例如高血糖、高血压、血脂异常、脂肪肝、阻塞性睡眠呼吸暂停综合征等)。 2. 本品适用于成人2型糖尿病患者的血糖控制: ● 单药治疗:单纯饮食控制和运动干预后血糖仍控制不佳的成人2型糖尿病患者; ● 联合治疗:在饮食控制和运动基础上,接受二甲双胍和/或磺脲类药物、 接受二甲双胍和/或钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)类药物治疗血糖仍控制不佳的成人2型糖尿病患者。(1) Long-term weight management, alongside dietary control and increased physical activity, in adults with an initial BMI of at least 28 kg/m2 (obesity), or at least 24 kg/m2 (overweight) with at least one weight-related comorbidity, such as hyperglycemia, hypertension, dyslipidemia, fatty liver or obstructive sleep apnea syndrome. (2) Glycemic control in adults with type 2 diabetes: as monotherapy when diet and exercise alone do not provide adequate control; or as combination therapy when control remains inadequate with metformin and/or a sulfonylurea, or metformin and/or a sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor), alongside diet and exercise.
- 适应症来源与口径
- 来源日期： 2026-05-06. 批准或修订日期为空或为占位值；尚未确认准确修订日期。Source date(s): 2026-05-06. An approval or revision date is blank or a placeholder; the exact revision date is not confirmed.
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。Complete official prescribing information obtained. Mainland China label.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 2025国家医保目录未匹配；待人工复核Not matched in the 2025 national list; manual review pending
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保核查说明
- 未在提取的目录中匹配到，并不证明被排除。复方制剂仍需人工复核。No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.